Introduction
In prostate cancer management the traditional goal has been to maximize patient survival, but recent advances in diagnosis and treatment have generated additional attention to the goal of maintaining and improving the quality of life of patients. Although these two goals are often complimentary, they may also present patients with dif®-cult choices in early or late stages of the disease. In some instances, patients may even ®nd more value in preserving quality of life than in extending length of life. 1 With increased interest in medical outcomes research, healthrelated quality of life (HRQOL) has become a variable that is often included as a primary endpoint in prostate cancer. HRQOL encompasses a wide range of human experiences, including the daily necessities of life, intrapersonal and interpersonal reasons to illiness, activities associated with professional ful®llment and personal happiness, and the overall sense of satisfaction that an individual experiences in life. 2, 3 Contemporary interpretations of HRQOL are based on the World Health Organization de®nition of health as not merely the absence of disease, but as a complete state of physical, emotional, and social wellbeing. 4 Most importantly, HRQOL involves patients' perceptions of their own health and ability to function in life. 5 HRQOL is now considered so critical that clinical cancer trials are said to be incomplete without it. 6±8 This is particularly true for prostate cancer, in which patients may live for years after the initial diagnosis. HRQOL after diagnosis and treatment may be in¯uenced by many factors, including age, education, marital status, tumor stage, and comorbidity. 9 In recent years, a growing body of HRQOL research has dramatically improved our understanding of how patients experience the consequences of this disease and its treatments.
10±16
The principal challenge of assessing HRQOL lies in quantifying relatively qualitative phenomena, a task with which most clinicians are unfamiliar. 17, 18 In order to accomplish this objective, the principles of psychometric test theory are applied. 19±22 This discipline provides the theoretical underpinnings for the science of survey research. Data are collected with HRQOL surveys, called instruments. Instruments typically contain questions, or items, that are organized into scales. Each scale measures a different aspect, or domain, of HRQOL. Some scales comprise dozens of items, while others may include only one or two items. Each item contains a stem (which may be a question or a statement) and a response set. Instruments can be self-administered by the patient or can be administered with the assistance of a neutral third-party interviewer in a standardized fashion. 23 HRQOL instruments must demonstrate the two fundamental psychometric statistical properties of reliability and validity. Reliability refers to the reproducibility of an instrument, while validity refers to its accuracy.
HRQOL instruments may be general or disease-speci®c. General HRQOL domains address the components of overall well being, while disease-speci®c domains focus on the impact of particular organic dysfunctions that affect HRQOL. 24, 25 General HRQOL instruments typically address general health perceptions, sense of overall well being, and function in the physical, emotional, and social domains. Disease-speci®c HRQOL instruments for prostate cancer patients focus on more directly relevant domains, such as anxiety about cancer recurrence, incontinence, impotence, and bowel dysfunction.
Established HRQOL instruments
General HRQOL instruments have been extensively researched and validated in many types of sick and well patients. The most widely used is the RAND Medical Outcomes Study 36-Item Health Survey (also known as the SF-36). 26±31 The SF-36 is considered by many to be gold standard for the measurement of general HRQOL. It is a 36-item, self-administered instrument that quanti®es HRQOL in multi-item scales that address eight different health concepts: physical function, social function, bodily pain, emotional well-being, energy/fatigue, general health perceptions, and role limitation due to physical or emotional problems. Two summary scales, a general health index and a mental health index, may also be calculated. 32 Each scale is scored from 0±100 with higher scores corresponding to better outcomes.
Other general HRQOL instruments include the Quality of Well-Being scale (QWB), 33±37 the Sickness Impact Pro®le (SIP), 38±40 and the Nottingham Health Pro®le (NHP).
41±44 A recent review cited over 50 different validated instruments designed to measure general HRQOL. 45 The number of disease-speci®c HRQOL instruments for prostate cancer has grown in recent years. Cancerspeci®c instruments, such as the Cancer Rehabilitation System (CARES), 46±49 CARES Short Form (CARES-SF), 50 and Functional Livingi IndexÐCancer (FLIC), 51, 52 have long been available, but two of these now have modules that are speci®c for prostate cancer. The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30), 53 a 30-item questionnaire that includes scales addressing various general HRQOL domains, has now been augmented with a 20-item prostate cancer instrument that includes scales for bowel symptoms, urinary symptoms, and sexuality. It has been used successfully in men with both localized 54, 55 and metastatic 56 prostate cancer. The Functional Assessment of Cancer Therapy (FACT) 57±60 is another useful cancer-speci®c instrument that has recently been enhanced with a prostate cancer scale, known as the FACT-P, 61 that addresses issues of particular concern to patients treated for this tumor.
The ®rst validated instrument speci®cally designed to measure HRQOL in men treated for localized prostate cancer is the University of California, Los Angeles (UCLA) Prostate Cancer Index. 62, 63 Built upon the SF-36, this selfadministered tool includes 20 prostate-speci®c items in six scales (urinary function and bother, sexual function and bother, and bowel function and bother), scored from 0± 100, with higher scores representing better outcomes. The UCLA Prostate Cancer Index is now in use in several national and international studies, and has recently been validated in Spanish. 64 Another disease-speci®c instrument, known as the Prostate Cancer Treatment Outcome Questionnaire (PCTO-Q) 65 was recently validated in a population of men with localized prostate cancer. It measures incidence and severity of speci®c changes in bowel, urinary and sexual functions and gives a summary score for each domain and an overall score by summing the three domain scores. Like the Prostate Cancer module for the EORTC QLQ-C30, the PCTO-Q does not distinguish between function and bother, a distinction that many patients ®nd important.
There are also several established instruments designed to measure the effect of sexual dysfunction on patients' HRQOL. The Brief Sexual Function Inventory 66 is an 11-item instrument that covers sexual drive, erection, ejaculation, perceptions of problems in each area, and overall sexual satisfaction. The Sexual Adjustment Questionnaire (SAQ), 67 a 108-item self-administered tool that measures six domains: libido, arousal, activity level, relationships, techniques, and orgasm. The SAQ was designed to examine the speci®c effects of cancer treatments on the sexual domains of HRQOL.
Metastatic prostate cancer
General and cancer-speci®c HRQOL have been studied in patients with metastatic prostate cancer by numerous researchers. Although these patients may suffer the ravages of advancing malignancy, 68 the literature bears out the observation that they generally maintain better general HRQOL than patients with other types of metastatic cancer. This is especially important in an often indolent disease, in which palliation may be the primary goal. 69 As the tumor progresses, overall quality of life eventually declines and takes on a greater role as an independent outcome variable. Indeed, in cases of painful bony metastases in patients with advanced hormone-refractory disease, improvements in HRQOL may be the primary endpoint for radiotherapy treatment. 70 In a study of 288 men with prostate cancer, Ganz et al 71 used the CARES to document the progressive worsening of quality of life as the prostate cancer advances, she also demonstrated that this instrument can be used to discriminate between various clinical stages of disease. Her ®ndings were con®rmed by Kornblith et al 72 who used the EORTC Prostate Cancer Quality of Life Questionnaire to survey patients and spouses, demonstrating that as disease progresses, steady HRQOL declines among patients are paralleled by increasing psychological distress among their spouses. Van Andel et al 73 also identi®ed general HRQOL and global health status as independent predictors of progression in patients with untreated metastatic disease.
Androgen ablation certainly affects sexual function and has psychosocial implications, but for most men this does not appear to hamper their overall quality of life. Lucas et al 74 examined 15 men immediately before and after bilateral orchiectomy. Although all men experienced a loss of sexual function, no changes were seen in global quality of life or sex role identity. Nonetheless, over half of the patients who were sexually active pre-operatively found the loss of sexual function disturbing. Litwin et al 75 used the UCLA Prostate Cancer Index to examine the longitudinal HRQOL effects of medical or surgical castration for newly diagnosed metastatic prostate cancer. They found diminished sexual function scores regardless of treatment type, but patients were not signi®cantly bothered by their sexual dysfunction. General HRQOL was well-preserved. In a methodologically similar study using the EORTC instrument in surgically or medically castrated men, da Silva et al 76, 77 showed that sexual functioning suffered in this group, they further demonstrated impairment in the general HRQOL domains of social role and fatigue, both of which impacted on patients' overall psychological well-being, they also noted that physicians did a poor job of accurately recording patients' quality of life concerns. Clark 86 and with the FACT and SAQ in a smaller study of radiotherapy for advanced disease. 87 Recent interest in measuring preferences, or utilities, for various health states has led to a better understanding of medical decision-making as individuals face dif®cult treatment choices between quality and quantity of life. For example, quality of life may be traded off in one domain against another when opting for early versus deferred androgen blockade. This treatment typically decreases sexual function but simultaneously alleviates painful metastases while creating the hope that therapy will extend their survival. 88±90 Patient utilities, either measured or unmeasured, also impact heavily in decisions regarding treatment for early stage tumors. At times patients' assessments of the utility of such health states may differ substantially from those of their spouses 91 or their physicians. 92 
Localized prostate cancer
The HRQOL impacts of early stage prostate cancer and its treatments have been studied extensively. Many experimental designs have been used to examine prostatespeci®c domains of HRQOL such as sexual, urinary, and bowel dysfunction, as well as domains of general HRQOL such as sexual, urinary, and bowel dysfunction, as well as domains of general HRQOL such as physical, emotional, and social well-being. While the best studies have relied on validated instruments, preliminary conclusions may be drawn from less methodologically rigorous work as well. Some researchers have compared patients selecting radical prostatectomy, radiation therapy, or expectant management with each other and with age-matched subjects without prostate cancer. Other investigators have used cross-sectional or longitudinal designs to focus exclusively on documenting the HRQOL effects of a single therapy. Most studies show that although early stage prostate cancer and its treatments may have the profound effects on the sexual, urinary, or bowel domains of HRQOL, these alterations are not typically re¯ected in the domains of general HRQOL.
Prostate-speci®c HRQOL in the sexual, urinary, and bowel domains has been well documented with the UCLA Prostate Cancer Index. 93 In a study of 528 men in a managed care population, general HRQOL was similar when comparing patients who had undergone surgery, radiation, or observation alone for clinically localized prostate cancer or when comparing them to a group of age-matched control subjects without prostate cancer. Among the subjects, signi®cant treatment group differences in HRQOL were identi®ed in the prostatespeci®c sexual, urinary, and bowel domains. Patients who had undergone radical prostatectomy had worse sexual and urinary function, but they were no more bothered than patients who had received radiation. Radiated patients had worse bowel function, but they were no more bothered than those undergoing surgery. Function and bother were clearly shown to be independent HRQOL domains. Interestingly, the prostate-speci®c HRQOL decrements did not translate into differences in general HRQOL.
Lim and colleagues 94 used the FLIC, the Pro®le of Mood States (POMS), 95 and an unvalidated disease-speci®c instrument to examine HRQOL in 136 men who had undergone radical retropubic prostatectomy and 60 men who had received external beam irradiation for clinically localized prostate cancer, they found that the prostatectomy group had worse sexual function and more urinary incontinence, while the radiation group had worse bowel function. Radiated patients who were incontinent perceived this as a greater problem than did incontinent patients in the prostatectomy group. The study also showed that sexual function correlated positively with physical vigor, and negatively with incontinence and depression, implying that impotence may have an effect on general HRQOL. When patients were asked if they would choose the same treatment again, 92% of prostatectomy patients and 87% of radiated patients said yes.
Shrader-Bogen et al 65 used the FACT-G and PCTO-Q to compare groups undergoing prostatectomy or radiation and also found that while sexual function was worse among the surgery patients, general HRQOL was similar between the two groups. These ®ndings have also been documented by Gburek et al 96 who reported results from 88 men undergoing surgery, radiation, or both, for early stage disease. They used a series of new disease-targeted questions on sexual, urinary, and bowel function, as well as overall satisfaction with care to show that although the speci®c complications of prostate cancer treatment are more common than previously reported, there was no difference between the quality of life experience of patients undergoing either surgery or radiation. Patients receiving both modalties were more likely to suffer more negative HRQOL outcomes.
Another study with an early version of the UCLA Prostate Cancer Index demonstrated that among men treated with surgery or radiation for localized prostate cancer, urinary dysfunction diminished HRQOL much more than did sexual dysfunction. Although negative functional outcomes were found more commonly than the published literature suggests, the degree of bother experienced by these patients did not necessarily correlate with the level of dysfunction. 97 Fowler and other members of the Prostate Patient Outcomes Research Team (PORT) 98, 99 used validated instruments to study a large national sample of Medicare bene®ciaries who had undergone radical prostatectomy, they documented that sexual and urinary dysfunction are much more common after radical prostatectomy than prviously reported, but they also showed that general HRQOL domains, such as physical and mental health, did not correlate well with decrements in prostate-speci®c HRQOL. Similar ®ndings have also been documented for patients treated at academic institutions in the US. 100 Talcott et al 101 examined a group of men who underwent nerve-sparing radical prostatectomy and compared them to those undergoing non-nerve sparing surgery. Using a newly validated HRQOL instrument, they found that patients having any type of nerve-sparing procedure had low levels of sexual function that were not signi®cantly different from men who underwent nonnerve sparing procedures. However, when their nervesparing population was broken down into one or both nerves spared, the bilateral nerve sparing group reported signi®cantly less impotence than non-nerve sparing group at one year. This study did not examine the degree to which sexual dysfunction bothered patients, nor did it examine general HRQOL in these patients. However, Rieker et al 102 demonstrated that sexual function and bother do have a signi®cant impact on quality of life in these patients and are distinct from other dimensions. Fortunately, a variety of treatments is available for men with impotence. When post-prostatectomy patients use erectile aids, their HRQOL in the sexual domains is returned to levels similar to men awaiting surgery. 103 In men treated with radical prostatectomy for early stage disease, Pedersen et al 104 carried out a longitudinal study of HRQOL changes for 18 months following surgery. The initial distress associated with diagnosis of cancer improved over time, although bother from erectile dysfunction persisted. Overall well-being was minimally affected. Interestingly, Klein et al 105 have shown that spouses experience greater psychological stress than their husbands after diagnosis and treatment for localized disease.
Barsilis et al 106 used the FLIC, POMS, and an unvalidated sexual function instrument to study 79 men who had undergone prostatectomy. They found that although impotence had little effect on most domains of general HRQOL, patients with better sexual function tended to have better scores in the physical vigor domain. Rosetti and Terrone 107 also found that erectile dysfunction in 161 men following radical prostatectomy did not have a great impact on general HRQOL.
Incontinence following prostate cancer treatment appears to have a greater impact on general HRQOL. Herr 108 demonstrated that among men who were incontinent after radical prostatectomy, 26% reported limitations in their usual physical activity and over half experienced moderate to severe emotional distress. Interestingly, 79% of those evaluated less than ®ve years after surgery said they would choose surgery again, despite their leakage problems. Lim et al 94 found that men who were incontinent following prostatectomy or radiation therapy were more likely to have poor scores in the emotional tension, physical fatigue and depression domains of the FLIC and POMS are less likely to have high physical vigor or social well being scores. In their study of men who underwent radical prostatectomy, Shrader-Bogen and colleagues 65 showed that 19% of subjects reported that their urinary problems affected their quality of life`quite a bit' or`very much.' Fossa and colleagues 109 also found lower urinary tract symptoms after treatment to be an independent predictor of global HRQOL in a logistic regression model. As continence improves during the months following prostatectomy, quality of life follows a similar course. 110 Similar results have been found for pelvic irradiation. When validating the prostate cancer module of the EORTC QLQ-C30, Borghede 54 used a population of men with localized prostate cancer who had undergone external beam therapy. Patients were found to have signi®cant decreases in the sexual domain, but relatively good general HRQOL. HRQOL scores on the sexuality and general scales did not correlate well with each other, again suggesting that general HRQOL tends to be well preserved, even in the setting of speci®c pelvic dysfunctions. Beard et al 111 used the SF-36 and the POMS to demonstrate that general HRQOL did not change signi®cantly in men receiving external beam radiation for prostate cancer. Bowel symptoms were common during the initial three months after therapy but improved at six months. Those receiving whole pelvis treatment fared worse than those receiving conformal therapy. Likewise, Caffo et al 112 used a validated instrument to show that, although 44% of men had signi®cant decreases in the sexual domain following radiation therapy, physical, psychological and relational well-being all remained good.
Fowler et al 113 studied HRQOL in 621 men who had undergone pelvic irradiation for prostate cancer. Patients were identi®ed through the National Institute of Health's Surveillance, Epidemiology, and End Results (SEER) program in three regions of the US. Compared to patients who had undergone radical prostatectomy, radiated patients had signi®cantly less incontinence (7% vs 32%) and erectile dysfunction (23% vs 56%), but signi®cantly more bowel dysfunction (10% vs 4%). Radiated patients also worried more about cancer recurrence than did those treated with surgery. In a comprehensive study of sexual function in 199 men who had undergone pelvic irradiation compared to 200 agematched controls, Fransson and Widmark 114 used a series of linear analogue scales to show that radiated patients were more than four times more likely to be impotent, except in those under 70 y old, in whom the frequency of sexual activity was almost equal to the control population without prostate cancer.
Other investigators examining the effect of erectile dysfunction on HRQOL following radiation have shown differences in general HRQOL. Helgason et al 115 used thè Radiumhemmet Scale of Sexual Functioning,' which includes an item that addresses global quality of life, to determine the effect of decreased sexual capacity on HRQOL in this patient population. They showed that sexual desire diminished 77% after treatment and that, although 66% of men still had an erection suf®cient for intercourse, 77% of men reported some loss of stiffness. More importantly, 50% of men reported that their overall quality of life had decreased much or very much as a direct result of their decrease in erectile function. Roach et al 116 noted similar outcomes using an unvalidated instrument.
Although patients undergoing radiation therapy tend to score better in their urinary domains than do those undergoing radical prostatectomy, these scores are still worse than in age-matched controls. 117 There is evidence that placement of an arti®cial urinary sphincter for incontinence following radical prostatectomy relives some but not all of the effects on disease-speci®c HRQOL.
118,119

Conclusions
The potential for therapeutic cure or prolonged survival in prostate cancer must be weighed against the risk of adverse effects on general or disease-speci®c HRQOL, when helping patients choose treatment for localized or metastatic disease. Several established, validated HRQOL instruments are now available for use in older men with prostate cancer across a broad scope of clinical disease stages. These instruments can provide urologists, radiation oncologists, medical oncologists, and primary care physicians with important data to guide individual case management and to conduct studies. The questionnaires are usually easy to self-administer and can provide additional information that the patient may not communicate to the physician during of®ce visits.
HRQOL in men with prostate cancer has taken on a more central role as a clinical endpoint, while its importance to patients has been increasingly recognized by physicians. In response, the body of literature in this area has grown dramatically in the last few years. During the nascence of this ®eld, studies were primarily descriptive, documenting what urologists knew but were unable or unwilling to articulate candidly. As the discipline has matured, so have the research questions. Today, investigation into the quality of life after diagnosis and treatment of prostate cancer is governed by the rigorous tenets of the scienti®c method. Research hypotheses now address complex issues, such as medical decision-making in the trade-off between quality and quantity of life, innate sociodemographic predictors of quality of life, the incorporation of quality of life into epidemiological models that factor in a variety of inputs and outcomes, and the development of clinical disease staging systems that include quality of life.
Disease-speci®c HRQOL outcomes must be compared among patients undergoing different modes of therapy.
General HRQOL must also be measured to facilitate comparison with patients treated for diabetes, heart disease, arthritis, other malignancies, and other chronic conditions. Quality of life outcomes must also be controlled for variations in comorbidity, severity of illness, sociodemographic case mix, as well as cost, quality, and access to care. Characterization of all domains must address not only the actual functions or dysfunctions, but also the relative importance of these issues to patients, how bothered they are, and what can be done to support them. 120 Of all the lessons learned from quality of life research in men with prostate cancer, perhaps the most important is that physicians caring for these men have come to understand more of the human factor in this disease. Our patients have much to teach us, and it is our duty to heed them. As we become more aware of the quality of life impairments suffered by our prostate cancer patients and their families, we can better equip ourselves with interventions to ameliorate these effects and improve the quality of care we provide.
